Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

PT-141 cycle length: what human studies ran

FDA-approvedAHuman trial evidence
Short answer: PT-141 has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • PT-141 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established PT-141 cycle length?
No cycle is defined. PT-141 is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of PT-141?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
PT-141 dosing reference Full research page

References

  1. VYLEESI (bremelanotide injection) prescribing information FDA label (DailyMed). 2024
  2. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials Obstet Gynecol. 2019
  3. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder Obstet Gynecol. 2019
  4. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction Int J Impot Res. 2004
  5. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra Int J Impot Res. 2004
  6. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist Proc Natl Acad Sci U S A. 2004
  7. Bremelanotide: an overview of preclinical CNS effects on female sexual function J Sex Med. 2007
  8. PT-141: a melanocortin agonist for the treatment of sexual dysfunction Ann N Y Acad Sci. 2003
  9. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization Peptides. 2006
  10. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (Study 301) ClinicalTrials.gov NCT02333071. 2015
  11. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (Study 302) ClinicalTrials.gov NCT02338960. 2015
  12. WADA Prohibited List US Food and Drug Administration. 2026
  13. Bremelanotide (CID 9941379) PubChem. 2026